Cell therapy for stroke: remaining issues to address before embarking on clinical trials.

@article{Borlongan2009CellTF,
  title={Cell therapy for stroke: remaining issues to address before embarking on clinical trials.},
  author={Cesario V. Borlongan},
  journal={Stroke},
  year={2009},
  volume={40 3 Suppl},
  pages={S146-8}
}
BACKGROUND AND PURPOSE Stroke remains a significant clinical unmet condition, with only 3% of ischemic patient population benefiting from the thrombolytic drug tissue plasminogen activator largely because of the drug's narrow 3-hour therapeutic window. Extending the stroke therapeutic window will greatly impact on treatment, care, and management of patients. Summary of Review- Cell therapy is appealing in this regard as it widens the stroke treatment opportunity by targeting the… CONTINUE READING